Comparative Proteomic Analysis of Peritoneal Dialysate from Chronic Glomerulonephritis Patients
Table 1
Identification of 10 altered spots, of which 4 showed higher levels in the early-stage PD samples, while 6 had higher levels in the middle stage.
Spot numbera
Protein name
Swiss-Prot accession no.
Mr (E/T)b (kDa)
pI (E/T)c
No. of identified peptides
Sequence coverage (%)
Mascot score
Fold change ± SDd
Alteration (M/E)
P01
Ig mu chain C region
P01871
68/49
6.5/6.4
5
10.2
215
Down
P02
Fibrinogen gamma chain
P02679
45/51
5.7/5.4
6
11.8
258
Down
P03
C-reactive protein
P02741
25/25
5.5/5.5
4
16.2
145
Down
P04
C-reactive protein
P02741
25/25
5.4/5.5
5
20.1
156
Down
P05
Ig delta chain C region
P01880
70/47
6.2/6.8
3
6.3
124
Up
P06
Alpha-1-antitrypsin
P01009
46/47
4.7/5.4
6
12.8
301
Up
P07
Histidine-rich glycoprotein
P04196
53/59
5.6/7.0
4
6.7
186
Up
P08
Histidine-rich glycoprotein
P04196
53/59
5.7/7.0
5
8.4
211
Up
P09
Apolipoprotein A-I
P02647
25/31
5.3/5.6
4
12.9
201
Up
P10
Serum amyloid P-component
P02743
27/25
5.7/6.1
6
24.5
298
Up
aThe spot numbers are designated in Figures 2(a) and 2(b).
bMr (E/T): experimental observation of apparent molecular weight in 2-DE/theoretical molecular weight calculated from protein sequence database.
cpI (E/T): experimental observation of pI in 2-DE/theoretical pI calculated from protein sequence database.
dFold change and standard deviation calculated from the protein spot intensity in middle-stage samples (M) versus that in early-stage samples (E).